Allogeneic Gamma Delta (γδ) T Cells for the Treatment of Glioblastoma

What this Trial Is About

Researchers are evaluating the safety and feasibility of a new treatment using genetically edited allogeneic gamma delta (γδ) T cells, called ABOUT γδT cells, in patients with glioblastoma multiforme (GBM). This first-in-human clinical study focuses on locally delivering these engineered cells, designed to selectively target and eliminate residual GBM cells after previous treatments. The study is led by Peking University Third Hospital and explores a novel approach to treating this aggressive brain tumor. The study involves three different dose levels of ABOUT γδT cells administered locally every 3 to 4 weeks: a low dose of 7x10^7 cells, a medium dose of 1.1x10^8 cells, and a high dose of 1.6x10^8 cells. Participants receive these treatments as part of a non-randomized, open-label trial without masking or placebo control. The treatments are given after previous therapies such as radiotherapy or systemic treatments, with a required waiting period before enrollment. Participants will be monitored closely for safety, including adverse events within 3 months and dose-limiting toxicities within 28 days after the first treatment. Researchers will also assess treatment responses and their duration during the first 3 months following cell administration. The study requires regular evaluations including MRI scans and lab tests to confirm organ function and disease status. The total participation period varies, with ongoing follow-up to track safety and treatment effects.

Allogeneic γδT Cells in Glioblastoma